Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA

Renaissance Pharma

Status: Withdrawn

Conditions: Urine Toxicology

Study type: Observational

Funder types: NETWORK; Industry

Identifiers

NCT02096172

2013-002

Details and patient eligibility

About

The objective of this study is to evaluate the impact of pharmacogenomic aspects of drug metabolism on the measurement of drug and drug metabolites on urine drug testing (UDT).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Able to provide written informed consent
• Pharmacogenomic testing within the last 60 days
• Planned UDT

Exclusion criteria

• Subject has chronic renal dysfunction, Chronic Kidney Disease Stage 4 or 5
• Subject has a history of abnormal hepatic function within the last 2 years (INR >1.2 not attributable to anticoagulant medications, AST or ALT >1.5x normal, or suspected cirrhosis)
• Subject has a history of malabsorption (short gut syndrome);
• Subject has a history of any gastric or small bowel surgery;
• Subject is currently hospitalized;
• Subject is currently receiving intravenous medication.